产品
编 号：F143308
分子式：C49H54N8O8
分子量：883
分子式：C49H54N8O8
分子量：883
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
250
In-stock
10mg
400
In-stock
50mg
960
In-stock
100mg
1440
In-stock
结构图
CAS No: 1377049-84-7
产品详情
生物活性：
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
体内研究：
Velpatasvir (10 mg/kg/d，口服) 单独或与 Sofosbuvir (HY-15005) (20 mg/kg/d) 联合使用可抑制 CCl4 诱导的非 HCV 大鼠模型中的肝纤维化[ 3]。Animal Model:CCl4-induced non-HCV rat model
Dosage:10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d)
Administration:p.o.
Result:Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.Inhibited hepatic stellate cells (HSCs).
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
体内研究：
Velpatasvir (10 mg/kg/d，口服) 单独或与 Sofosbuvir (HY-15005) (20 mg/kg/d) 联合使用可抑制 CCl4 诱导的非 HCV 大鼠模型中的肝纤维化[ 3]。Animal Model:CCl4-induced non-HCV rat model
Dosage:10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d)
Administration:p.o.
Result:Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.Inhibited hepatic stellate cells (HSCs).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备